← boardnext 2028-06-15next 2030-08
IRD
Opus Genetics, Incdistress 6/10 · elevated risk$2.95-3%today-49% from 52w high
Lead: LCA5
Revenue
pre-revenue
Liquidity
$60M
Runway
1.5 yrs
Shares 1y
+36%
Price & events
+18.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.3%
1D
-10.1%
1W
-27.7%
1M
-43.4%
3M
+15.2%
6M
+145.8%
1Y
+43.2%
2Y
-29.4%
5Y
-57.9%
All
Overview
- Market Cap
- $240.12M
- Enterprise Value
- $181.36M
- Volume
- 34.68K
- 52 Week Range
- $1.06 – $5.75
- Total Shares
- 81.40M
- Float Shares
- 63.68M
- Short %
- 10.48%
- % Held by Insiders
- 11.06%
- % Held by Institutions
- 55.14%
- RVOL
- 0.03x
- Beta
- 0.56
Pipeline stages · 2 programs
AAV8.hLCA5
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
OPGx-RDH12
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-06-15 Estimated 50% readout ~2028-07-30 | Phase 1/2 | AAV8.hLCA5 | LCA5 | — | recruiting |
| 2030-08 Estimated 50% readout ~2030-09-15 | Phase 1/2 | OPGx-BEST1rare pediatricorphanrmat | ARB, BVMD, Autosomal-Dominant Bestrophinopathy, Best Vitelliform Macular Dystrophy | — | recruiting |
| 2032-12 Estimated 50% readout ~2033-01-15 | Phase 1/2 | OPGx-RDH12rare pediatricorphanrmat | Leber Congenital Amaurosis, Leber Congenital Amaurosis (LCA), LCA5 | — | not yet recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 18
- on or prior to March 31, 2028Guided 40%filing acceptanceFiled (NDA/BLA)OPGx-LCA5 · FDA Application Acceptance Date for OPGx-LCA5SEC 8-K
- approximately one year after dosingGuided 40%readoutPhase 3OPGx-LCA5 · Topline clinical data expected one year after dosing.SEC 8-K
- second half of 2027trial initiationsecondaryPhase 1OPGx-RHO · Expected to initiate clinical testing globally.SEC 8-K
- first quarter of 2027trial initiationsecondaryPhase 1OPGx-MERTK · Expected to initiate clinical testing at Cleveland Clinic Abu Dhabi.SEC 8-K
- second half of 2026Guided 55%trial initiationsecondaryPhase 3OPGx-LCA5 · Dosing in adaptive pivotal Phase 3 trialSEC 8-K
- by the end of 2026Guided 40%PDUFAPDUFAPhentolamine Ophthalmic Solution 0.75% · FDA decision on sNDASEC 8-K
- September 2026readoutPhase 1/2OPGx-BEST1 · Three-month topline data from Cohort 1.SEC 8-K
- 2026-08-12earningsEarningsEarnings releaseyahoo
- first half of 2026readoutPhase 3Phentolamine Ophthalmic Solution 0.75% · Topline results from LYNX-3 pivotal trialSEC 8-K
- mid-2026readoutPhase 1/2OPGx-BEST1 · 3-month results from entire Cohort 1SEC 8-K
- this quarterconferencedata presentationsecondaryPhase 1/2OPGx-BEST1 · Initial data from BIRD-1 trial at Macula SocietySEC 8-K
- Thursday, January 15, at 8:15 a.m. PTconferencedata presentationsecondaryCorporate presentation at J.P. Morgan Healthcare ConferenceSEC 8-K
- January 15, 2026 at 8:15 a.m. Pacific Timeconferencedata presentationsecondaryCorporate presentation at 44th Annual J.P. Morgan Healthcare Conference.SEC 8-K
- by late 2025regulatory submissionFiled (NDA/BLA)OPGx-RDH12 · IND filing targeted with FDA by late 2025.SEC 8-K
- second half of 2025regulatory submissionFiled (NDA/BLA)Phentolamine Ophthalmic Solution 0.75% · Plan to file NDA with FDASEC 8-K
- 2025-11-06fda agreementOPGx-LCA5 · Successful Type B RMAT meeting with FDA; feedback on CMC and pivotal trial design. FDA acknowledged unmet need and regulatory flexibility.SEC 8-K
- 2025-07-22partnershipOPGx-RDH12 · Funding and license agreement with Global RDH12 Alliance for up to $1.6M to co-develop OPGx-RDH12 gene therapy.SEC 8-K
- 2025-06-23partnershipOPGx-MERTK · Funding agreement with RD Fund for up to $2 million, non-dilutive, to support preclinical development.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $11 (+258% upside) · 18 analysts
- 2026-07-06BTIGBuy
- 2026-07-06Chardan CapitalBuy
- 2026-06-18Chardan CapitalBuy
- 2026-06-17HC Wainwright & Co.Buy
- 2026-06-16BTIGBuy
- 2026-06-15CitizensMarket Outperform
Competitors — LCA5
- none identified
Recent news
- 2026-07-223 E Network Advances Proprietary AI SaaS Platform for Companion Robots - GlobeNewswire
- 2026-07-203 E Network Finalizes Custom Edge AI SoC Architecture for - GlobeNewswire
- 2026-07-20IRD warns of fines and prison sentences for willful tax defaulters - Ada Derana
- 2026-07-20Unresolved IRD weaknesses put tax reforms at risk - Daily FT
- 2026-07-19Opus Genetics (IRD) Hovers Near Support Amid Modest Decline - High Low Breadth - dars.gov.et
- 2026-07-19IRD to file legal action against liable tax dodgers - dailynews.lk
- 2026-07-19IRD warns willful tax defaulters face fines and jail - The Morning
- 2026-07-19Fines, Jail & Grace Period: 7 Key Tax Updates from IRD - Newswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.